New immunotherapeutic therapeutic approaches
The first PD1 antibody has already been approved after failure of chemotherapy in squamous cell carcinoma of the lung. In addition to an improved tolerability, the survival of patients with this therapy is better than with chemotherapy.
Also in adenocarcinoma of the lung the approval of such drugs can be expected soon. In trials, they are also tested in small cell lung cancer.